Physiologically, angiogenic growth factors such as vascular endothelial growth factor (VEGF) are reduced in AD patients with their levels correlated to the severity of cognitive impairment [84], and treatment with VEGF was reported to reverse E4-induced pathologies in humanized-E4 mice [85]. Here, VEGFA is linked to Cognitive impairment.